Synthesis and Effects of 4,5-Diaryl-2-(2-alkylthio-5-imidazolyl) Imidazoles as Selective Cyclooxygenase Inhibitors by Mohammad Reza Saberi et al.
Original article  
Iranian Journal of Basic Medical Sciences 
Vol. 13, No. 4, Autumn 2010, 225-231 
Received: Mar 6, 2010; Accepted: May 26, 2010 
 
 
 
 Iran J Basic Med Sci, Vol. 13, No. 4, Autumn 2010     225
 
Synthesis and Effects of 4,5-Diaryl-2-(2-alkylthio-5-imidazolyl) Imidazoles as 
Selective Cyclooxygenase Inhibitors 
 
1Mohammad Reza Saberi, *
2Farzin Hadizadeh, 
1Mohsen Imenshahidi, 
2Hadi Shakeri, 
2Seyedeh Toktam 
Ziaee, 
1Mohammad Ali Ghafuri, 
1Ramin Sakhtianchi, 
1Zohreh Badieyan, 
1Somieh Hajian
 
 
 
Abstract 
 
Objective(s) 
In recent years highly selective COX-2inhibitors were withdrawn from the market because of an increased 
risk of cardiovascular complications. In this study we were looking for potent compounds with moderate 
selectivity for cox-2. So, four analogues of 4, 5-diaryl-2-(2-alkylthio-5-imidazolyl) imidazole derivatives  
were synthesized and their anti-inflammatory and anti-nociceptive activities were evaluated on male BALB/c 
mice (25-30 g). Molecular modeling and in vitro COX-1 and COX-2 isozyme inhibition studies were also 
performed.  
Materials and Methods 
2-(2-Alkylthio-5-imidazolyl)-4,5-diphenylimidazole  compounds were obtained by the reaction of benzyl 
with 2-alkylthio-1-benzylimidazole-5-carbaldehyde, in the presence of ammonium acetate. Spectroscopic 
data and elemental analysis of compounds were obtained and their structures elucidated. Anti-nociception 
effects were examined using writhing test in mice. The effect of the analogues (7.5, 30, 52.5 and 75 mg/kg) 
against acute inflammation were studied using xylene-induced ear edema test in mice. Celecoxib (75 mg/kg) 
was used as positive control. 
Results 
All four analogues exhibited anti-nociceptive activity against acetic acid induced writhing, but did not show 
significant analgesic effect (P< 0.05) compared with celecoxib. It was shown that analogues injected 30 min 
before xylene application reduced the weight of edematic ears. All analogues were found to have less 
selectivity for COX-2 in comparison to celecoxib.  
Conclusion 
Injected doses of synthesised analogues possesses favorite anti-nociceptive effect and also has anti-
inflammatory effects, but comparing with celecoxib this effect is not significantly different. On the other 
hand selectivity index for analogues is less than celecoxib and so we expect less cardiovascular side effects 
for these compounds. 
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Introduction  
The use of nonsteroidal anti-inflammatory drugs 
(NSAIDs) for the treatment of inflammation and 
pain is often accompanied by adverse 
gastrointestinal and renal side effects. Their anti- 
inflammatory activity results from  inhibition          
of cyclooxygenases (COXs), which catalyzes   
the bioconversion of arachidonic acid to 
prostaglandins. However, inhibition of COXs 
may lead to undesirable side effects. Nowadays, 
it is well established that there are at least two 
COX isozymes, COX-1 and COX-2 (1, 2). The 
constitutive COX-1 isozyme is produced in a 
variety of tissues and appears to be important to 
the maintenance of physiological functions such 
as gastroprotection and vascular homeostasis (3).
 
Alternatively, the COX-2 isozyme is induced by 
mitogenic and proinflammatory stimuli linking 
its involvement to inflammatory processes (4). 
Thus, selective inhibition of COX-2 over COX-1 
is useful for the treatment of inflammation and 
inflammation-associated disorders with reduced 
gastrointestinal toxicities when compared with 
NSAIDs. In addition to role of COX-2 in 
rheumatoid arthritis and osteoarthritis, it is also 
implicated in colon cancer and angiogenesis         
(5, 6). Recent studies have shown that the 
progression of Alzheimer’s disease is reduced 
among some users of NSAIDs. Chronic 
treatment with selective COX-2 inhibitors may 
therefore slow the progress of Alzheimer’s 
disease without causing gastrointestinal damage 
(7). So more selective COX-2 inhibitors were 
developed as a new generation of NSAIDs with 
diminished GI side effects. However, highly 
selective rofecoxib and valdecoxib were 
withdrawn from the market because of an 
increased risk of cardiovascular complications. 
COX-2 mediates the biosynthesis of prostacyclin, 
a vasodilator and inhibitor of platelet aggregation, 
the inhibition of prostacyclin production by 
selective COX-2 inhibitors might account for 
their adverse cardiovascular effects (8, 9). So we 
are looking for compounds with moderate 
selectivity for cox-2 to diminish possible 
cardiovascular side effects.  
Diarylheterocycles, and other central ring 
pharmacophore templates, have been extensively 
studied as selective COX-2 inhibitors. All these 
tricyclic molecules possess 1,2 diaryl substitution 
on a central hetero- or carbocyclic ring system 
(see structures 1–5 in Figure 1) (10-14). Synthesis 
and analgesic activities of tetracyclic  systems,        
2-aryl-4,5-diphenylimidazole derivatives (see 
structures 6 in Figure 1), has also been reported 
previously (15).  
As part of our program to design new types of 
tetracyclic moderate selective COX-2 inhibitors, 
we  now  report  synthesis,  anti-inflammatory,          
and  anti-nociceptive  activity  of  a  group  of            
4,5-diaryl-2-(2-alkylthio-5-imidazolyl) imidazole 
derivatives. The target 4,5-diaryl-2-(2-alkylthio-5-
imidazolyl) imidazole derivatives [8a-d]  were   
synthesized via the route outlined in Figure 2. 
Accordingly, an appropriate imidazole 
carbaldehyde [7a-d] was treated with benzil in the 
presence of ammonium acetate to give the target 
4,5-diaryl-2-(2-alkylthio-5-imidazolyl) imidazole 
derivatives [8a-d]. 
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Figure 1. Representative examples of COX-2inhibitors.  
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Figure 2. Synthesis of compounds 8a-d from appropriate 
imidazole aldehyde 7a-d.  
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Materials and Methods 
Chemical methods 
Melting points were determined on 
Electrothermal Capillary apparatus and are 
uncorrected. The IR spectra were obtained using 
a Perkin-Elmer Model 1000. 
1H NMR were 
obtained on Bruker Ac-80 spectrophotometer 
and chemical shifts (δ) are in ppm relative to 
internal tetramethylsilane. C, H, N analyses were 
within ±0.4% of theoretical values. Compounds 
7a-d were prepared as described previously (16).  
 
General  procedure  for  preparation  of             
4,5-diaryl-2-(2-alkylthio-5-imidazolyl) 
imidazoles (8a-d). 
Benzil (0.01 mol) and imidazole-5-carbaldehyde 
[7] were reacted with ammonium  acetate          
(0.08 mol) in glacial acetic acid and refluxed for 
6 hr.  
 
4,5-Diphenyl-2-(1-methyl-2-methylthio-
5-imidazolyl) imidazole [8a]. 
This compound was obtained in 66% (71.5%) 
yield; IR (KBr): 3050 cm
-1 (NH); 
1H NMR 
(CDCl3): 8.43 (bs,1H, NH), 7.7-7.6 (m, 4H, 
arom), 7.45-7.3 (m,7H, arom), 4.25 (s,3H, 
NCH3), 2.50 (s,3H, CH3S); Anal. Calcd. for 
C20H18N4S: C, 69.34; H, 5.24; N, 16.17. 
Found: C, 68.33; H, 5.31; N, 15.97. 
 
4,5-Diphenyl-2-(1-methyl-2-ethylthio-5-
imidazolyl) imidazole [8b]. 
This compound was obtained in 56% (63%) 
yield; mp 189-190 
oC; IR (KBr): 3050 cm
-1  
(NH); 
1H NMR (CDCl3): 8.43 (bs,1H, NH), 
7.7-7.6 (m,4H,arom), 7.45-7.3 (m,7H,arom), 
4.25 (s,3H, NCH3), 3.50 (q, 2H, CH2S), 1.46 
(t, 3H,CH3); Anal. Calcd. For C21H20N4S: C, 
69.97; H, 5.59; N, 15.54. Found: C, 70.11; H, 
5.41; N, 15.34. 
 
4,5-Diphenyl-2-(1-benzyl-2-ethylthio-5-
imidazolyl) imidazole [8c]. 
This compound was obtained in 66% (79%) 
yield; mp 91.5-92.9 
oC; IR (KBr): 3050 cm
-1  
(NH);  (CHCl3): 3100 (NH), 1650 cm
-1 (CO); 
1H NMR (CDCl3): 8.43 (bs,1H,NH), 7.5-6.8 
(m, 16H, arom), 5.6 (s, 2H, CH2N), 3.50 (q, 
2H, CH2S), 1.46 (t, 3H,CH3): Anal. Calcd. For 
C27H24N4S: C, 74.28; H, 5.54; N, 12.83. 
Found: C, 74.12; H, 5.39; N, 12.53. 
 
4,5-Diphenyl-2-(1-benzyl-2-methylthio-
5-imidazolyl) imidazole [8d] 
This compound was obtained in 53% yield; 
mp 185-186
 oC; IR (CHCl3): 3100 cm
-1 (N-H); 
1H NMR (CDCl3): 8.43 (bs, 1H, NH), 7.5-6.8 
(m, 16H, arom), 5.6 (s, 2H, CH2N),  2.50        
(s, 3H, CH3S); Anal. Calcd. For C26H22N4S: C, 
73.90; H, 5.25; N, 13.26. Found: C, 73.73; H, 
5.14; N, 13.55. 
 
Modeling and docking studies 
Similarity search of COX-2 against PDB bank 
using BLAST program in EXPASY server was 
turned up with many results in which PGH-2 
of mice encoded as Q05769 having 604 amino 
acids was chosen as the best candidate for 
docking study due to quite high identity, 86%. 
In such case we did not need to model the 
human enzyme and the mice one was used 
directly instead. 
The ligand molecules were constructed using 
Chem 3D 2003 and Hyperchem 6 and were 
energy minimized for 1000 iterations reaching 
a convergence of 0.01 kcal/mol and finally 
saved as PDB files for further docking 
procedure. Meanwhile, the protein PDB file 
was downloaded from RCSB site as code: 
1PXX  followed by water molecules removal 
using viewerlite program. The final corrected 
PDB file of the protein and designed ligands 
were submitted to AutoDock tools to run 
doking process. Furthermore, a selective 
COX-2 inhibitor named SC-588 which has 
been co-crystalized with murine COX-2 was 
obtained from RCSB site. 
The purpose of docking is to search for 
favorable binding configuration between the 
small flexible ligands and the rigid protein. 
Docking studies were performed using 
Autodock software Version 3.0 (17). 
Searching was conducted within a specified 
3D docking box using annealing based on the 
Monte Carlo method and MMFF94 molecular 
mechanics force field for 8000 iterations. The 
size of the box was set 40 angstrom in all 
aspects. Essential pdbqs, gpf and dpf files of 
both protein and ligands were produced in  
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AutoDock tools while further docking was 
performed applying Autodock3 using related 
commands in Linux. Docked structures looked 
very similar to the minimized structures 
obtained initially and the quality of the docked 
structures was evaluated by measuring the 
intermolecular energy of the ligand-enzyme 
assembly. The results will be discussed later in 
this article. 
 
Biological evaluation 
In vitro cyclooxygenase (COX) inhibition 
assay 
The ability of the test compounds 8a-d to 
inhibit ovine COX-1 and COX-2 was 
determined using a colorimetric COX (ovine) 
inhibitor  screening  assay  which  utilizes        
the peroxidase component of cyclooxygenase.  
The peroxidase activity is assayed 
colorimetrically by monitoring the appearance 
of oxidized N,N,N',N'-tetramethyl-p-
phenylenediamine (TMPD) at 590 nm. 
 
Pharmacological methods 
The experiments were performed under the 
Animals (scientific procedures) Act of 1986 
and conform to the National Institutes of 
Health guidelines for the use of experimental 
animals. This study was carried out on male 
BALB/c mice (25-30 g) from Razi Institute, 
Mashhad, Iran.   Animals were housed in 
plastic cages in an animal room maintained at 
21±2 °C on a 12 hr dark cycle and supplied 
with food and water ad libitum. 
 
The maximum non- fatal doses 
Different doses of compounds were dissolved 
in normal saline containing 0.5% CMC and 
injected intraperitoneally (i.p.) into groups of 
six mice and the number of deaths was 
counted at 48 hr after treatment.   
 
Writhing test 
Anti-nociceptive effects of compounds were 
examined using writhing test in mice. One 
hour after  administration of the compounds 
(7.5, 30, 52.5 and 75 mg/kg)  and celecoxib 
(75 mg/kg)  to the male BALB/c mice 
weighing 25–30 g, the mice were given an   
intraperitoneal  injection of  0.7% (v/v) acetic 
acid solution (volume of injection 0.1 ml/10 
g). The number of writhes produced in these 
animals was counted for 30 min (18). 
Celecoxib was used as positive and normal 
saline as negative control.  
 
Xylene-induced ear edema 
The effect of the analogues against acute 
inflammation was studied using xylene-
induced ear edema test in mice. Thirty minutes 
after i.p. injection of the compounds (7.5, 30, 
52.5 and 75 mg/kg) and celecoxib (75 mg/kg), 
0.03 ml of xylene was applied to the anterior 
and posterior surfaces of the right ear. The left 
ear was considered as control. Two hours after 
xylene application the mice were sacrificed 
and both ears were removed. Circular sections 
were taken using a cork borer with a diameter 
of 7 mm, and weighed. The increase in weight 
caused by the irritant was measured by 
subtracting the weight of the untreated left ear 
section from that of the treated right ear 
sections (18).  
 
Statistical analysis 
The data were expressed as ED50 of 
compounds and tested with analysis of 
variance followed by the multiple comparison 
test of Tukey–Kramer. 
 
Results  
In vitro cyclooxygenase (COX) inhibition 
assay of test compounds 8a-d showed that 
none of compounds to be more selective than 
celecoxib. Selectivity index for test 
compounds was found to be between 1.66-1.75 
and that of celecoxib was 3.22 (Table 1).  
    
 
Table 1. In vitro COX-1 and COX-2 enzyme inhibition 
data. 
IC50
a(nM)  compound 
COX-1 COX-2 
COX-2 SI
b 
 
8a 339.3  195  1.74 
8b 350  200  1.75 
8c 280.5  170  1.65 
8d 290.5  175  1.66 
celecoxib 483 150 3.22 
 
a Values are mean values of two determinations 
acquired using an ovine COX-1/COX-2 assay kit, where 
the deviation from the mean is <10% of the mean value. 
b In vitro COX-2 selectivity index (COX-1 IC50/COX-2 
IC50).  
Novel 4-imidazolyl dihydropyridines as selective COX-II inhibitors  
 
 Iran J Basic Med Sci, Vol. 13, No. 4, Autumn 2010     229
The maximum non fatal doses of compounds 
were 75 mg/kg. Injection of four doses of 
analogues (7.5, 30, 52.5 and 75 mg/kg) in mice 
showed analgesic effect in writhing test. 
Celecoxib (75 mg/kg) was used as positive 
control. All four analogues exhibited anti 
nociceptive activity against acetic acid induced 
writhing, but did not show significant (P> 0.05) 
analgesic effect compared with celecoxib. 
Values of ED50 of compounds and positive 
control in writhing test have been shown in 
Table 2.  
In xylene-induced ear edema test, all four 
analogues exhibited anti-inflammatory activity 
but did not show significant effect compared 
with celecoxib (P> 0.05). Values of ED50 of 
compounds and positive control in xylene-
induced ear edema test have been shown in 
Table 3.  
Four designed structures were docked into 
the active site of murine COX-2 as well as 
celecoxib, indometacin, diclofenac and sc558 
where the last one was directly derived from 
an X-Ray crystallography file. As seen in 
Figure 3 all mentioned structures fill the same 
cavity of the enzyme and show more or less 
the same size. 
 
Table 2. Values of ED50 of compounds in writhing test. 
 
Statistics 
(comparison 
with 
celecoxib) 
ED50 
(mg/kg) 
Compound 
n.s.  56.82±0.95  8a 
n.s.  51.26±0.13  8b 
n.s.  40.06±0.60  8c 
n.s.  42.91±0.62  8d 
*  10.2±0.21  Celecoxib 
n.s. P> 0.05; * P< 0.05 
 
 
Table  3. Values of ED50 of compounds in xylene-
induced ear edema test.  
 
Statistics 
(comparison 
with 
celecoxib) 
ED50 
(mg/kg) 
Compound 
n.s.  121.66±0.82  8a 
n.s.  111.22±0.40  8b 
n.s.  87.74±0.47  8c 
n.s.  96.89±0.59  8d 
*  11.54±0.56  Celecoxib 
n.s. P> 0.05; * P< 0.05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. some inhibitors as well as natural substrate in 
the active site of murine COX-2. Indometacine= green. 
Diclofenac= pink. Celecoxib= Yellow. Sc558= Blue. 
An inhibitor of ours= white. Prostaglandin= Orange. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Compound 8d docked in the active site of murine 
COX-2 isozyme. Five helices have made the active site. 
 
Two important residues, TYR385 and 
SER530 are highlighted in Figure 1. Changing 
these residues will lead to loss of complete 
action of the enzyme (19). Five helices 
surround the ligands in the active site. This has 
been clearly indicated in Figure 4.     
Investigating the docking results clears that 
no hydrogen binding is involved in ligand-
protein interaction while hydrophobe-
hydrophobe interactions instead is clearly 
seen. Ligplot diagrams (20) confirm this 
conclusion where bulky amino acids, TRP, 
TYR and PHE surround the ligands in the 
active site (Figure 5). Another interesting 
result is consideration of a big hydrophobic   
pocket at the distant terminal of helix 6 where 
accommodates bulky substitutions on ligands 
such as bis-phenyl and naphthalene.  
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Figure 5. The ligplot diagram of compound 8d in the active 
site. Many hyrophobe and bulky residues have surrounded 
the ligand. No hydrogen binding is being seen. 
 
Discussion 
In vitro biological evaluations showed that the 
synthesized compounds exhibited moderate 
selectivity, less than that of celecoxib, but their 
IC50 for inhibition of COX-2 was not 
significantly different from that of celecoxib 
(Table 1). All the synthesized compounds 
were docked in the active site of murine COX-
2 isozyme and their mode of interaction 
compared with that of known COX-2 
inhibitors like celecoxib (Figure 3). Ligplot 
diagrams showed, in contrast to celecoxib no 
hydrogen binding was involved in ligand-
protein interaction while hydrophobe-
hydrophobe interactions instead was clearly 
seen (Figure 5). It may be the reason for less 
selectivity of our compounds in comparison to 
celecoxib. Although selective COX-2 
inhibitors had a significantly lower incidence 
of gastrointestinal adverse effects, but 
increasing selectivity also increases the 
potential for adverse cardiovascular 
thrombotic events  by tipping the balance of 
prostacyclin/thromboxane in favor of 
thromboxane, a prethrombotic eicosanoid (8), 
so our compounds with moderate selectivity 
may have less cardiovascular side effects (9). 
In vivo comparison of the anti-nociceptive 
and anti-inflammatory activity of compounds 
(Table 2 and 3) also had no significant 
difference with celecoxib. These results were 
in agreement with in vitro results. But it was 
found that compounds having benzyl 
substituent on imidazole ring (8c, d) were 
more potent than those having methyl 
substituent [8a, b]. In vitro results showed the 
same order. Investigation of docking results 
showed the presence of a big hydrophobic 
pocket at the distant terminal of helix 6, where 
may accommodates bulky substitutions on 
ligands such as benzyl substituent (Figure 4). 
This may describe the higher potency of 
compounds (8c, d) with benzyl substituent. 
 
Conclusion 
It is concluded that injected doses of 
synthesised analogues possess favourite anti-
nociceptive effect and also have anti-
inflammatory effect, but comparing with 
celecoxib this effect is not significantly 
different. On the other hand selectivity index 
for analogues is less than celecoxib and so we 
expect less cardiovascular side effects for 
these compounds. 
 
Acknowledgment 
The authors are thankful to the financial 
support of the Research Council of Mashhad 
University of Medical Sciences, Mashhad, 
Iran. The authors declare that they have no 
conflict of interests. 
 
References 
1. Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P. The induction and suppression of prostaglandin H2 
synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990; 265:16737-16740. 
2. Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene 
encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991; 88:2692-2696. 
3. Smith WL, Dewitt  DL. Prostaglandin endoperoxide H synthases-1 and -2. Adv Immunol 1996; 62:167-215. 
4. Herschman HR. Prostaglandin synthase 2. Biochim Biophys Acta 1996; 1299:125-140. 
5. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib,a specific cyclooxygenase-2 
inhibitor, against colon carcinogenesis. Cancer Res 1998; 58:409-412. 
6. Katori M, Majima M. Cyclooxygenase-2: Its rich diversity of roles and possible application of its selective 
inhibitors. Inflamm Res 2000; 49:367-392.  
Novel 4-imidazolyl dihydropyridines as selective COX-II inhibitors  
 
 Iran J Basic Med Sci, Vol. 13, No. 4, Autumn 2010     231
7. Vane JR, Botting RM. Anti-inflammatory drugs and their mechanism of action. Inflamm Res 1998; 47:S78-87. 
8.  Bing RJ, Lomnicka M. Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events? J Am Coll Cardiol 
2002; 39:521-522. 
9. Chen  C-S, Tan C-M, Huang  C-H, Chang  L-C, Wang  J-P, Cheng  F-C, et al. Discovery of 3-(4-bromophenyl)-
6-nitrobenzo[1.3.2]dithiazolium ylide 1,1-dioxide as a novel dual cyclooxygenase/5-lipoxygenase inhibitor that 
also inhibits tumor necrosis factor-[alpha] production. Bioorg  Med Chem 2010; 8:597-604. 
10. Penning TD, Talley  JJ, Bertenshaw  SR, Carter  JS, Collins  PW, Docter S. Synthesis and biological evaluation of the 
1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-
1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem 1997; 40:1347-1365. 
11. Prasit P, Wang  Z, Brideau  C, Chan CC, Charleson S, Cromlish W, et al.The discovery of rofecoxib, [MK 966, 
VIOXX®, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone],an orally active cyclooxygenase-2 inhibitor. 
Bioorg Med Chem Lett 1999; 9:1773-1778. 
12. Friesen RW, Dubé D, Fortin R, Frenette R, Prescott S, Cromlish W, et al. Novel 1,2-diarylcyclobutenes: 
Selective and orally active COX-2inhibitors. Bioorg Med Chem Lett 1996; 6:2677-2682. 
13. Talley  JJ, Brown  DL, Carter JS, Graneto MJ, Koboldt CM, Masferrer JL, et al. 4-[5-Methyl-3-phenylisoxazol-4-yl]- 
benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem 2000; 43:775-777. 
14. Zarghi A, Rao PN, Knaus EE. Design and synthesis of new rofecoxib analogs as selective cyclooxygenase-2 
(COX-2) inhibitors: replacement of the methanesulfonyl pharmacophore by a N-acetylsulfonamido bioisostere. J 
Pharm Pharm Sci 2007; 10:159-167. 
15. Isikdag I, Meric A. Syntheses and analgesic activities of some 2-substituted-4,5-diphenyl and 1,2-disubstituted-
4,5-diphenyl imidazole derivatives. Boll Chim Farm 1999; 138:24-29. 
16. Hadizadeh F, Vosooghi R. Synthesis of α-[5-(5-Amino-1,3,4-thiadiazol-2-yl)-2-imidazolylthio]acetic acids. J 
Heterocyclic Chem 2008; 45:1477-1479. 
17. Morris  GM, Doodsell  DS, Holliday RS, Huey R, Hart WE, Belew RK, et al. Automated docking using a 
Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998; 19:1639-1662. 
18. Hosseinzadeh H, Ramezani M, Salmani G. Antinociceptive, anti-inflammatory and acute toxicity effects of 
Zataria multiflora Boiss extracts in mice and rats. J Ethnopharmacol 2000; 73:379-385. 
19. Rowlinson SW, Kiefer JR, Prusakiewicz JJ, Pawlitz JL, Kozak KR, Kalgutkar AS, et al. A novel mechanism of 
cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385. J Biol Chem 2003; 278:45763-45769. 
20. Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein-
ligand interactions. Protein Eng 1995; 8:127-134. 
 
 